前列腺放疗中基于MRI的计算机辅助分割第一部分:量化前列腺及危及器官的人间观察者变异及其对放射剂量的影响
25例前列腺癌患者接受MRI引导的低剂量率前列腺近距离放疗,7名观察者在50幅MRI上勾画前列腺、外尿道括约肌、精囊腺、直肠和膀胱。3名放射肿瘤学家组(G1)的前列腺和外尿道括约肌观察者间变异低于其他4名临床观察者组(G2),但外尿道括约肌变异在所有器官中最高,前列腺剂量学参数存在较大差异。
要点
- G1组前列腺观察者间变异低于G2组(计划MCC 0.906 vs 0.870,P<0.001)。
- 外尿道括约肌观察者间变异在所有器官中最高,G1组仍低于G2组。
- 前列腺剂量学参数存在较大差异,G1组最大绝对ΔD90计划为76.223 Gy。
核心结论
- 尽管MRI在前列腺癌放射治疗管理中是最优的,但前列腺和外尿道括约肌仍存在显著的观察者间变异。
研究设计与样本
- 25例前列腺癌患者接受基于MRI的低剂量率前列腺近距离放疗,采集3D T2加权序列用于治疗计划、3D T2/T1加权序列用于质量评估,共50幅MRI。
- 7名参与低剂量率前列腺近距离放疗工作流程的观察者在所有50幅MRI上勾画前列腺、外尿道括约肌、精囊腺、直肠和膀胱。
- 通过测量轮廓相似性指标、器官体积差异和独特观察者配对间的剂量学参数差异评估观察者间变异,并将3名放射肿瘤学家组(G1)的测量结果与其余4名临床观察者组(G2)进行比较。
主要发现
- 前列腺观察者间变异G1组低于G2组(马修斯相关系数[MCC],G1 vs G2:计划-0.906 vs 0.870,p<0.001;植入后-0.899 vs 0.861,p<0.001)。
- 外尿道括约肌观察者间变异在两组合所有器官中最高,但G1组较低(MCC,G1 vs G2:计划-0.659 vs 0.402,p<0.001;植入后-0.684 vs 0.398,p<0.001)。
- 观察到前列腺剂量学参数存在较大差异(G1最大绝对前列腺ΔD90:计划-76.223 Gy,植入后-36.545 Gy;G1最大绝对前列腺ΔV100:计划-13.927%,植入后-8.860%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Quantifying the interobserver variability (IoV) of prostate and periprostatic anatomy delineation on prostate MRI is necessary to inform its use for treatment planning, treatment delivery, and treatment quality assessment. MATERIALS AND METHODS: Twenty five prostate cancer patients underwent MRI-based low-dose-rate prostate brachytherapy (LDRPBT). The patients were scanned with a 3D T2-weighted sequence for treatment planning and a 3D T2/T1-weighted sequence for quality assessment. Seven observers involved with the LDRPBT workflow delineated the prostate, external urinary sphincter (EUS), seminal vesicles, rectum, and bladder on all 50 MRIs. IoV was assessed by measuring contour similarity metrics, differences in organ volumes, and differences in dosimetry parameters between unique observer pairs. Measurements from a group of 3 radiation oncologists (G1) were compared against those from a group consisting of the other 4 clinical observers (G2). RESULTS: IoV of the prostate was lower for G1 than G2 (Matthew's correlation coefficient [MCC], G1 vs. G2: planning-0.906 vs. 0.870, p < 0.001; postimplant-0.899 vs. 0.861, p < 0.001). IoV of the EUS was highest of all the organs for both groups, but was lower for G1 (MCC, G1 vs. G2: planning-0.659 vs. 0.402, p < 0.001; postimplant-0.684 vs. 0.398, p < 0.001). Large differences in prostate dosimetry parameters were observed (G1 maximum absolute prostate ΔD90: planning-76.223 Gy, postimplant-36.545 Gy; G1 maximum absolute prostate ΔV100: planning-13.927%, postimplant-8.860%). CONCLUSIONS: While MRI is optimal in the management of prostate cancer with radiation therapy, significant interobserver variability of the prostate and external urinary sphincter still exist.
引用
- Sanders JW, Mok H, Hanania AN, et al. Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. Radiother Oncol. 2021. PMID: 34921895. doi:10.1016/j.radonc.2021.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。